Skip to main content
Premium Trial:

Request an Annual Quote

Genedrive HCV ID Kit Gets CE-IVD Marking

NEW YORK (GenomeWeb) – Genedrive announced today that its Genedrive HCV ID kit has achieved CE certification under the EU Medical Devices Directive. Genedrive's product functions as a qualitative molecular assay for hepatitis C.

According to Genedrive, the HCV assay runs on the company's Genedrive instrument, a PCR thermocycling device that provides rapid nucleic acid amplification and detection results. The assay does not require a separate viral RNA extraction process; instead, it is performed directly via a small, 25 microliter plasma sample. Using lyophilized PCR reagents packaged into a single-use, disposable cartridge, the assay delivers clinical results within 90 minutes.

"The combination of national screening programs, the availability of cost-effective treatment, and consequently a growing demand for molecular diagnostics is an area we can contribute to in a meaningful way," Genedrive CEO David Budd said in a statement.

Performance evaluation studies to support the assay's CE marking demonstrated sensitivity and specificity fulfilling requirements published by the Foundation for Innovation in New Diagnostics, Genedrive said.

Late last year, Genedrive received CE-IVD approval for its IL28B SNP human genotyping test, clearing it for sale in Europe.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.